{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:55:05Z","timestamp":1792068905103,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102070001"],"award-info":[{"award-number":["202102070001"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077050"],"award-info":[{"award-number":["22077050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2026A1515012632"],"award-info":[{"award-number":["2026A1515012632"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118808","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:34:04Z","timestamp":1789860844000},"page":"118808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers"],"prefix":"10.1016","volume":"143","author":[{"given":"Licheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bmc.2026.118808_bb0005","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1021\/acsmedchemlett.4c00269","article-title":"Discovery of IRAK1\/4\/pan-FLT3 kinase inhibitors as treatments for acute myeloid leukemia","volume":"15","author":"Hoyt","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"10.1016\/j.bmc.2026.118808_bb0010","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bmc.2026.118808_bb0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tips.2026.01.009","article-title":"Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy","volume":"47","author":"Thapa","year":"2026","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.bmc.2026.118808_bb0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118808_bb0025","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.bmc.2026.118808_bb0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12943-025-02455-y","article-title":"Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia","volume":"24","author":"Lo Schiavo","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118808_bb0035","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2019.11051","article-title":"Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics","author":"Tao","year":"2019","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.bmc.2026.118808_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104367","article-title":"Targeting FLT3 for treating diseases: FLT3 inhibitors","volume":"30","author":"Rong","year":"2025","journal-title":"Drug Discov Today"},{"issue":"25","key":"10.1016\/j.bmc.2026.118808_bb0045","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118808_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/2040620717721459","article-title":"Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis","volume":"8","author":"Gallogly","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.bmc.2026.118808_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.bmc.2026.118808_bb0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118808_bb0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2012.191","article-title":"Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors","volume":"27","author":"Williams","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bmc.2026.118808_bb0070","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2026.118808_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118808_bb0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2026.118808_bb0085","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1039\/D5MD00095E","article-title":"Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation","volume":"16","author":"Pogash","year":"2025","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2026.118808_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115974","article-title":"Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia","volume":"264","author":"Liu","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2026.118808_bb0095","doi-asserted-by":"crossref","first-page":"21939","DOI":"10.1021\/acs.jmedchem.5c02332","article-title":"Development of dual FLT3 and CHK1 PROTACs for the treatment of AML","volume":"68","author":"Lian","year":"2025","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118808_bb0100","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118808_bb0105","doi-asserted-by":"crossref","first-page":"17303","DOI":"10.1021\/acs.jmedchem.5c00831","article-title":"Discovery of potent dual PROTAC degraders targeting BET-kinase to overcome FLT3 inhibitor resistance","volume":"68","author":"Xiang","year":"2025","journal-title":"J Med Chem"},{"issue":"48","key":"10.1016\/j.bmc.2026.118808_bb0110","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1021\/jacs.8b10320","article-title":"Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion","volume":"140","author":"Burslem","year":"2018","journal-title":"J Am Chem Soc"},{"issue":"2","key":"10.1016\/j.bmc.2026.118808_bb0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking protacs from discovery to the clinic","volume":"10","author":"Pike","year":"2026","journal-title":"Nat Rev Chem"},{"issue":"15","key":"10.1016\/j.bmc.2026.118808_bb0120","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2026.118808_bb0125","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","article-title":"Discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12\/13 PROTAC degrader","volume":"67","author":"Zhou","year":"2024","journal-title":"J Med Chem"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:35:34Z","timestamp":1792067734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":25,"alternative-id":["S0968089626002646"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118808","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118808"}}